Literature DB >> 16324768

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Jian-Min Tang1, Quan-Ying He, Rui-Xia Guo, Xiu-Jun Chang.   

Abstract

Akt, a downstream mediator of phosphatidylinositol 3-kinase (PI3K), is a signal transduction protein that plays a central role in tumorigenesis. The tumor suppressor gene PTEN negatively regulates the PI3K/Akt signaling pathway. However, the roles of Akt and PTEN function in patients with non-small cell lung cancer (NSCLC) is not well established. To clarify roles of expression of phosphorylated Akt (p-Akt) and loss of PTEN expression in biological behavior and prognosis of NSCLC. Immunohistochemical staining was used to determine the expression of p-Akt and PTEN in 20 cases of normal lung tissues and 102 cases patients with NSCLC. All patients with NSCLC were followed from 3 to 60 months. The positive incidence of p-Akt expression and loss incidence of PTEN expression in NSCLC were 41.2% (42/102) and 46.1% (47/102), while negative of p-Akt expression (0%, 0/20) and positive of PTEN expression (100%, 20/20) in normal lung tissues. Overexpression of p-Akt and loss of PTEN expression were correlated to poor differentiation, lymph node involvement, distant metastasis and late stages. A significant negative correlation was observed between expression of p-Akt and PTEN (r = -0.425, P < 0.001). Patients with p-Akt positive expression (42/102) and loss of PTEN expression (47/102) showed significantly worse 5 years survival rate and median survival time than relevant those with p-Akt negative expression (14.29% versus 33.33%, 14 months versus 32 months, Log-rank test X(2) = 14.24, P < 0.001) and PTEN positive expression (10.64% versus 38.18%, 15 months versus 40 months, Log-rank test X(2) = 21.06, P < 0.001). A univariate analysis revealed that smoking, tumor size, lymph node involvement, distant metastasis, stage, p-Akt and loss of PTEN expression were significant correlative factors with prognosis. The result of multivariate Cox analysis showed that smoking, stage and loss of PTEN expression were independent prognosticators. p-Akt is overexpressed and accompanied by the loss of PTEN in clinical specimens of NSCLC. Both p-Akt and PTEN are concerned with invasion and metastasis of NSCLC. Loss of PTEN expression is an independent poor prognostic factor for patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16324768     DOI: 10.1016/j.lungcan.2005.10.003

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  127 in total

1.  Non-small cell lung carcinoma therapy using mTOR-siRNA.

Authors:  Hirochika Matsubara; Kenji Sakakibara; Tamo Kunimitsu; Hiroyasu Matsuoka; Kaori Kato; Noboru Oyachi; Yoh Dobashi; Masahiko Matsumoto
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

2.  The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer.

Authors:  Pei-Jye Voon; Byoung Chul Cho; Wee-Lee Yeo; Ross A Soo
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

3.  Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.

Authors:  A Black; D Morris
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

4.  PTEN gene is infrequently hypermethylated in human esophageal squamous cell carcinoma.

Authors:  Zhenguo Sun; Na Ji; Mingming Bi; Shuai Wang; Xiangyan Liu; Zhou Wang
Journal:  Tumour Biol       Date:  2015-02-28

Review 5.  Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Authors:  Po Yee Yip
Journal:  Transl Lung Cancer Res       Date:  2015-04

6.  Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.

Authors:  Hua-Chuan Zheng; Koichi Tsuneyama; Hiroyuki Takahashi; Shigeharu Miwa; Toshiro Sugiyama; Boryana Konstantinova Popivanova; Chifumi Fujii; Kazuhiro Nomoto; Naofumi Mukaida; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-18       Impact factor: 4.553

7.  Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progression.

Authors:  Sharad S Singhal; James Figarola; Jyotsana Singhal; Lokesh Nagaprashantha; David Berz; Samuel Rahbar; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

8.  Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

Authors:  Akihiko Yoshizawa; Junya Fukuoka; Shigeki Shimizu; Konstantin Shilo; Teri J Franks; Stephen M Hewitt; Takeshi Fujii; Carlos Cordon-Cardo; Jin Jen; William D Travis
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

9.  Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer.

Authors:  Tetyana V Pedchenko; Adriana L Gonzalez; DingZhi Wang; Raymond N DuBois; Pierre P Massion
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-19       Impact factor: 6.914

10.  Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer.

Authors:  Shun-Lai Li; Chia-Hsin Huang; Chih-Chan Lin; Zih-Ning Huang; Jyh-Haur Chern; Hsiao-Yin Lien; Yong-Yi Wu; Chia-Hui Cheng; Chia-Yu Chang; Jiunn-Jye Chuu
Journal:  Invest New Drugs       Date:  2009-12-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.